Aliada Therapeutics, Inc. — Form D
Aliada Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-12-30. The offering totals $32.0M, of which $32.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-12-30
- Form: D
- Accession: 0001870878-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $32.0M
- Amount sold: $32.0M
- Investors: 5
- Date of first sale: 2022-12-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-469243
Issuer
- Name: Aliada Therapeutics, Inc.
- CIK: 0001870878
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 200 BERKELEY STREET, 23rd FLOOR, BOSTON, MA, 02116
- Phone: 617-721-0860
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Marian J Nakada | Director | Boston, MA |
| Joshua J Resnick | Director | Boston, MA |
| Adam J Rosenberg | Director | Boston, MA |
| Jim J Sullivan | Director | Boston, MA |
| Laura J Tadvalkar | Director | Boston, MA |
| Sari Epstein | Executive Officer | Boston, MA |
| Adam J Rosenberg | Executive Officer | Boston, MA |
Other filings by this issuer (1)
More